MyOme's Avatar

MyOme

@myome.com.bsky.social

We help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies.

7 Followers  |  7 Following  |  6 Posts  |  Joined: 22.11.2024  |  1.5412

Latest posts by myome.com on Bluesky

Post image

Join us at #ACMG2025

We will be showcasing our upcoming rare disease products in our showcase, Advancing Rare Disease Diagnostics, on March 19th at 12:15 PM PST. Lunch will be provided. Register here: lnkd.in/gP847QVR

12.03.2025 16:14 β€” πŸ‘ 0    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Live webinar: Innovations in Clinical Testing for Oncology & Rare Diseases. Taking place on march 6th at 11am ET.

Live webinar: Innovations in Clinical Testing for Oncology & Rare Diseases. Taking place on march 6th at 11am ET.

Our next roundtable covers the challenges & strategies for integrating vast, multi-modal datasets into their clinical testing workflows. hello.dnanexus.com/webinar/inno...
@dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social h.bsky.social @myome.com

25.02.2025 17:28 β€” πŸ‘ 2    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

Today we are excited to launch CAD iPRS β€” a cutting-edge, genome-wide polygenic risk score for coronary artery disease. Empowering primary care to identify high-risk patients and personalize prevention strategies.

Read more here: prnewswire.com/news-release...

27.02.2025 16:38 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

MyOme’s Dr. Akash Kumar will speak at WashU Medicine’s Rare Disease Day event on:

πŸ“… Feb 20 | 1:45PM PT / 3:45PM CT
🧬 Shortening Diagnostic Timelines for Rare Diseases – A Whole-Genome Platform Approach

19.02.2025 18:38 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Innovations in Clinical Testing for Oncology & Rare Diseases Clinical testing for oncology and rare diseases faces unique challenges that demand innovative solutions. Patient recruitment and retention remain significant hurdles, with stringent eligibility crite...

Join our discussion on clinical testing innovations that are enabling organizations to derive insights into #oncology & #raredisease. hello.dnanexus.com/webinar/inno...

@dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social @myome.com

13.02.2025 19:43 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
MyOme and Novi Health Collaborate to Bring Whole Genome Testing to Employer Health Programs /PRNewswire/ -- MyOme, a leading clinical innovation whole genomic analysis and polygenic risk modelling (PRS) company announced a strategic partnership with...

We're partnering with Novi Health to bring whole genome testing to employer health programs. Through this collaboration, employees and their families gain access to whole genome sequencing, integrated risk (with PRS) reports, and expert genetic counseling.
prn.to/4jzWF7T

30.01.2025 17:04 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

MyOme's CEO, Premal S. Shah, PhD, is excited to speak at #PMWC2025 on Feb 6 at 2 PM. We'll discuss integrated polygenic risk scores for breast cancer & coronary artery disease. Learn more: pmwcintl.com/program/ #PrecisionMedicine

14.01.2025 17:49 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Natera and MyOme Announce Launch of iPRSβ„’ for Breast Cancer Risk Assessment Cross-ancestry polygenic risk score now offered with the Empowerβ„’ hereditary cancer test AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testin...

Big news! 🧬 Natera & MyOme launch iPRSβ„’, a personalized tool to assess breast cancer risk. Backed by research, iPRS integrates >1M genetic markers & clinical inputs for accurate, cross-ancestry insights.

Learn more: ow.ly/mGsJ50UntLt
#BreastCancer #Genetics

09.12.2024 17:38 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 0    πŸ“Œ 2

@myome.com is following 7 prominent accounts